Status and phase
Conditions
Treatments
About
This study will evaluate the safety, tolerability and pharmacokinetics of CR011-vcMMAE in patients who have unresectable stage III or stage IV melanoma and have failed no more than 1 line of prior cytotoxic therapy. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks at escalating doses until the maximum tolerated dose (MTD) is reached. Once the MTD is defined, 18-32 patients will be enrolled to further evaluate the safety and efficacy of CR011-vcMMAE at this dose level. Additional dosing schedules of CR011-vcMMAE will also be explored.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female with age ≥ 18 years.
Progressive or new metastatic melanoma, stage III or IV.
Measurable disease by CT / MRI
Failure of no more than 1 line of prior cytotoxic therapy.
Adequate bone marrow, renal and hepatic function
Karnofsky PS ≥ 70%.
Estimated life expectancy > 3 months.
Signed informed consent approved IRB and ability to comply with the study or monitoring procedures.
Subjects with evaluable disease are eligible in dose-escalation cohorts
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal